Edwards Lifesciences is a medical device company located in California, United States, which is part of the Healthcare sector, and is traded under the ticker EW on the NYSE exchange.
Edwards Lifesciences stock last closed at $86.45, down 0.91% from the previous day, and has increased 2.49% in one year. It has overperformed other stocks in the Medical Devices industry by 0.19 percentage points. Edwards Lifesciences stock is currently +42.73% from its 52-week low of $60.57, and -10.06% from its 52-week high of $96.12.
At the moment, there are 601M shares of EW outstanding. The market value of EW is $51.96B. In the last 24 hours, 3.12M EW shares were traded.
How to Buy Edwards Lifesciences Stock
Wondering how to invest in Edwards Lifesciences stock? Here's how.
Choose where to buy Edwards Lifesciences stock: You need to decide on a stock brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you choose where to buy Edwards Lifesciences stock.
Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Fund your investment account: Choose your method of payment and add your details.
Analyze Edwards Lifesciences stock: The Edwards Lifesciences ticker symbol is EW. Is Edwards Lifesciences stock a good investment? Should you buy shares of EW? How do EW's underlying business fundamentals look? Do top analysts think Edwards Lifesciences is a good buy? Why has EW's stock price moved recently? (Hint: Our stock research tools can help you evaluate if EW is a good stock to buy).
Place your EW trade: Decide if you will purchase EW shares at the current market price or use a limit order to purchase EW shares at a particular price.
Keep an eye on your EW investment: Create a watchlist to watch your new investment in Edwards Lifesciences shares.
Step 1: Choose where to buy Edwards Lifesciences stock
You will need an online brokerage account in order to access the NYSE market and buy EW shares.
A brokerage account enables you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
You can invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to world markets: From Technology to Utilities, New York to Tokyo — you can fill your portfolio with stocks from the globe's leading stock exchanges.
Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by creating an account with eToro now.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create your brokerage account
Now that you've picked the right brokerage, you'll need to fill out some personal details so you are able to buy EW stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Edwards Lifesciences stock
Once you have chosen the best place to buy Edwards Lifesciences stock, it's absolutely critical to analyze their stock prior to buying, so you actually comprehend the risk and opportunity.
Edwards Lifesciences stock data
EW Price
$86.45
1w %
-5.43%
1y %
2.49%
5y %
46.31%
P/E
37.42x
P/B
7.81x
P/S
8.73x
PEG
1.41x
Revenue
$6.00B
Earnings
$1.40B
Fore. Rev. Growth
9.27%
Fore. Earn. Growth
26.57%
Market Cap
$51.96B
Next Earnings
Apr 24, 2024
Next Dividend
N/A
Edwards Lifesciences Due Diligence Checks
WallStreetZen was built to help average investors do more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on EW's stock page.
How is EW stock valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge EW's fair value.
Using relative valuations ratios:
EW could be overvalued based on its P/E ratio of 37.42x, relative to Medical Devices industry P/E ratio of 28.61x
EW may be overvalued based on its P/B ratio of 7.81x, relative to Medical Devices industry P/B ratio of 3.63x
EW may be overvalued based on its PEG ratio of 1.41x
You can do additional valuation research on EW's stock here.
A look at EW Cashflows and Balance Sheet
Passed Financial Due Diligence Checks:
There are more short-term assets than long-term liabilities on the EW balance sheet.
EW earnings of $1.62B is not sufficient to cover its interest payments.
EW's operating cash flow of $895.80M allows it to safely service it's debt of $694.90M.
There are more short-term assets than short-term liabilities on the EW balance sheet.
Total EW debt is lower than 5 years ago, relative to shareholder equity.
EW has a low debt to equity ratio of 0.4.
Failed Financial Due Diligence Checks:
EW profit margin has gone down from 28.3% to 23.4% in the past year.
Is it a good time to buy EW stock, according to analysts?
Out of 11 Equities analysts who research EW, the consensus analyst rating on EW is a Buy
Please note that analyst ratings are not recommendations, nor are they investment advice.
Latest EW Analyst Upgrades/Downgrades
Suraj Kalia, a bottom 7% analyst from Oppenheimer maintains EW with a buy rating and raises their EW price target from $93.00 to $100.00, on Mar 18, 2024.
Rick Wise, a top 8% analyst from Stifel Nicolaus maintains EW with a hold rating and raises their EW price target from $70.00 to $83.00, on Feb 7, 2024.
Larry Biegelsen, a top 13% analyst from Wells Fargo upgrades EW to a strong buy rating and announces their EW price target of $94.00, on Feb 2, 2024.
Richard Newitter, a top 6% analyst from Truist Securities maintains EW with a strong buy rating and raises their EW price target from $78.00 to $84.00, on Dec 22, 2023.
Mike Polark, a top 18% analyst from Wolfe Research downgrades EW to a sell rating and announces their EW price target of $57.00, on Nov 28, 2023.
Last year, EW earnings were $1.40B. During the last 5 year, EW's earnings have grown by 14.97% per year. This was faster than the Medical Devices industry average of 9.19%.
Last year, EW revenue was $6.00B. Over the past five year, EW's revenue has gone up by 10.03% per year. This was slower than the Medical Devices industry average of 13.47%.
No, Edwards Lifesciences doesn't provide an income stream by paying out dividends.
What do other investors have to say about EW?
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your EW trade
There are two main types of orders:
Market order: A market order is an order to buy or sell a security at the best possible price. Market orders are mostly fine for most investors.
Limit order: A limit order allows you to buy or sell a security at a specific price (or better). If you want to be sure you're buying or selling at a particular dollar amount, place a limit order.
Press the Open button and your broker will execute your order.
If you require additional help investing in stocks on eToro, click the helpful video below:
How much does it cost to buy one Edwards Lifesciences share?
As of Apr 18, 2024, it costs $86.45 to buy one share of Edwards Lifesciences stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.116 shares of EW.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.